MAPK1 and melanoma: Furthermore, CD47 expression was upregulated by treatment with vemurafenib in a panel of fresh melanoma isolates carrying the BRAFV600E mutation (Figure 1G) [25].Taken together, these results suggest that treatment with BRAF or MEK inhibitors upregulates CD47 expression due to reactivation of ERK.